

# Magali Olivier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6320569/publications.pdf>

Version: 2024-02-01

80  
papers

11,086  
citations

81900

39  
h-index

91884

69  
g-index

90  
all docs

90  
docs citations

90  
times ranked

16721  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure. <i>International Journal of Cancer</i> , 2022, 150, 374-386.	5.1	4
2	The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. <i>Cell Death and Differentiation</i> , 2022, 29, 1071-1073.	11.2	53
3	Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. <i>Human Mutation</i> , 2021, 42, 223-236.	2.5	81
4	The International Collaboration for Cancer Classification and Research. <i>International Journal of Cancer</i> , 2021, 148, 560-571.	5.1	32
5	PVAmpliconFinder: a workflow for the identification of human papillomaviruses from high-throughput amplicon sequencing. <i>BMC Bioinformatics</i> , 2020, 21, 233.	2.6	2
6	Anthropometry, body shape in early-life and risk of premenopausal breast cancer among Latin American women: results from the PRECAMA study. <i>Scientific Reports</i> , 2020, 10, 2294.	3.3	10
7	A quantitative model to predict pathogenicity of missense variants in the TP53 gene. <i>Human Mutation</i> , 2019, 40, 788-800.	2.5	21
8	Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans. <i>Genome Research</i> , 2019, 29, 521-531.	5.5	57
9	Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. <i>PLoS ONE</i> , 2019, 14, e0210372.	2.5	12
10	Project profile: a multicenter study on breast cancer in young women in Latin America (PRECAMA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	7
11	Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by TP53 variants. <i>Human Mutation</i> , 2018, 39, 1061-1069.	2.5	29
12	MA11.05 A Case-Control Study to Test the Use of ctDNA in the Early Detection of SCLC Reveals TP53 Mutations in Non-Cancer Controls. <i>Journal of Thoracic Oncology</i> , 2017, 12, S405-S406.	1.1	0
13	Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. <i>Genome Research</i> , 2017, 27, 1475-1486.	5.5	90
14	IARC TP53 Database. , 2017, , 2193-2198.		0
15	TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. <i>Human Mutation</i> , 2016, 37, 865-876.	2.5	589
16	Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer. <i>EBioMedicine</i> , 2016, 10, 117-123.	6.1	153
17	MutSpec: a Galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes. <i>BMC Bioinformatics</i> , 2016, 17, 170.	2.6	44
18	Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. <i>PLoS ONE</i> , 2015, 10, e0126762.	2.5	18

#	ARTICLE	IF	CITATIONS
19	Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1873-1881.	2.5	21
20	Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. <i>European Respiratory Journal</i> , 2015, 46, 1773-1780.	6.7	114
21	Abstract 4748: Revealing the molecular portrait of triple negative breast tumors from an understudied population through omics analysis of formalin-fixed and paraffin-embedded tissues. , 2015, , .		0
22	Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002. <i>Clinical Cancer Research</i> , 2014, 20, 4613-4624.	7.0	195
23	Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. <i>Carcinogenesis</i> , 2014, 35, 807-815.	2.8	29
24	Modelling mutational landscapes of human cancers in vitro. <i>Scientific Reports</i> , 2014, 4, 4482.	3.3	83
25	Abstract 305: Ultra-low coverage exome sequencing of FFPE tumor specimens identifies exposure to carcinogenic aristolochic acid. , 2014, , .		0
26	Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. <i>Mutation Research - Reviews in Mutation Research</i> , 2013, 753, 41-49.	5.5	55
27	TP53 Somatic Mutations: Prognostic and Predictive Value in Human Cancers. , 2013, , 127-146.		2
28	A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. <i>Cell Death and Disease</i> , 2013, 4, e492-e492.	6.3	43
29	Assessing TP53 Status in Human Tumors: Lessons from Breast Cancer. , 2013, , 147-165.		1
30	Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma. <i>Sarcoma</i> , 2012, 2012, 1-6.	1.3	23
31	Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EU-ELC cohort. <i>European Respiratory Journal</i> , 2012, 40, 177-184.	6.7	92
32	Upper urinary tract urothelial cancers: where it is A:T. <i>Nature Reviews Cancer</i> , 2012, 12, 503-504.	28.4	22
33	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. <i>Breast Cancer Research</i> , 2012, 14, R70.	5.0	52
34	Sarcomas in TP53 germline mutation carriers. <i>Cancer</i> , 2012, 118, 1387-1396.	4.1	189
35	p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. <i>Cancer Letters</i> , 2011, 300, 215-224.	7.2	25
36	Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. <i>Cell Death and Differentiation</i> , 2011, 18, 1815-1824.	11.2	173

#	ARTICLE	IF	CITATIONS
37	Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. <i>Current Opinion in Oncology</i> , 2011, 23, 88-92.	2.4	41
38	Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. <i>Cancer Gene Therapy</i> , 2011, 18, 2-11.	4.6	151
39	Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 35-42.	2.5	27
40	TP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child - evidence for chimerism involving a common mutant founder haplotype: case report. <i>BMC Cancer</i> , 2011, 11, 449.	2.6	34
41	p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. <i>International Journal of Cancer</i> , 2011, 128, 1813-1821.	5.1	29
42	IARC TP53 Database. , 2011, , 1799-1802.		1
43	Abstract 5538: Sarcomas in TP53 germline mutation carriers. , 2011, , .		0
44	Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. <i>Current Opinion in Oncology</i> , 2010, 22, 64-69.	2.4	91
45	Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. <i>Human Mutation</i> , 2010, 31, 143-150.	2.5	116
46	p53 regulates the transcription of its 133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. <i>Oncogene</i> , 2010, 29, 2691-2700.	5.9	60
47	TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. <i>Cold Spring Harbor Perspectives in Biology</i> , 2010, 2, a001008-a001008.	5.5	1,494
48	TP53 Mutations in Human Cancers: Selection versus Mutagenesis. <i>Molecular Biology Intelligence Unit</i> , 2010, , 1-18.	0.2	1
49	Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2009, 15, 7719-7725.	7.0	87
50	Somatic mutation databases as tools for molecular epidemiology and molecular pathology of cancer: Proposed guidelines for improving data collection, distribution, and integration. <i>Human Mutation</i> , 2009, 30, 275-282.	2.5	14
51	Recent advances in p53 research: an interdisciplinary perspective. <i>Cancer Gene Therapy</i> , 2009, 16, 1-12.	4.6	140
52	TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. <i>Journal of Medical Genetics</i> , 2009, 46, 766-772.	3.2	64
53	Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. <i>Human Mutation</i> , 2008, 29, 1273-1281.	2.5	41
54	Influence of TP53 gene status on treatment response in breast cancer cells. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 104.	2.2	0

#	ARTICLE	IF	CITATIONS
55	Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. <i>Cancer Letters</i> , 2008, 261, 21-25.	7.2	94
56	Prognostic and Predictive Value of TP53 Mutations in Human Cancer. , 2007, , 321-338.		13
57	The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. <i>Cancer Letters</i> , 2007, 245, 96-102.	7.2	170
58	Response to "Germline TP53 R337H mutation is not sufficient to establish Li-Fraumeni or Li-Fraumeni-like syndrome" by Ribeiro et al.. <i>Cancer Letters</i> , 2007, 247, 356-358.	7.2	1
59	Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. <i>Human Mutation</i> , 2007, 28, 622-629.	2.5	1,441
60	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. <i>Oncogene</i> , 2007, 26, 2157-2165.	5.9	796
61	Patterns of TP53 Mutations in Human Cancer: Interplay Between Mutagenesis, DNA Repair and Selection. , 2007, , 293-319.		4
62	Patterns of TP53 Mutations in Human Cancer: Interplay between Mutagenesis, DNA Repair and Selection. , 2007, , 293-319.		0
63	Prognostic and Predictive Value of TP53 Mutations in Human Cancer. , 2007, , 321-338.		0
64	Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. <i>Human Mutation</i> , 2006, 27, 163-172.	2.5	21
65	Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. <i>Nucleic Acids Research</i> , 2006, 34, 1317-1325.	14.5	295
66	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.. <i>Clinical Cancer Research</i> , 2006, 12, 1157-1167.	7.0	495
67	TP53 mutations as biomarkers for cancer epidemiology in Latin America: Current knowledge and perspectives. <i>Mutation Research - Reviews in Mutation Research</i> , 2005, 589, 192-207.	5.5	16
68	Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients. <i>Breast Cancer Research</i> , 2005, 7, 1.	5.0	0
69	Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. <i>Human Mutation</i> , 2004, 24, 21-34.	2.5	46
70	The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2004, 41, 551-583.	6.1	31
71	TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. <i>IARC (International Agency for Research on Cancer) Scientific Publications</i> , 2004, , 247-70.	0.4	83
72	Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. <i>Cancer Research</i> , 2003, 63, 6643-50.	0.9	350

#	ARTICLE	IF	CITATIONS
73	Differential Activation of p53 by the Various Adducts of Mitomycin C. Journal of Biological Chemistry, 2002, 277, 40513-40519.	3.4	50
74	Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Human Mutation, 2002, 19, 149-164.	2.5	122
75	The IARC TP53 database: New online mutation analysis and recommendations to users. Human Mutation, 2002, 19, 607-614.	2.5	1,107
76	Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 2002, 21, 7435-7451.	5.9	961
77	TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Seminars in Cancer Biology, 2001, 11, 353-360.	9.6	56
78	TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. Mutagenesis, 2001, 16, 551-553.	2.6	47
79	Relaxed cell-cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-type p53. Molecular Carcinogenesis, 1998, 23, 1-12.	2.7	23
80	Modulation of DNA Topoisomerase I Activity by p53. Biochemistry, 1996, 35, 5778-5786.	2.5	99